Nuvation Bio Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $62.9M | $7.9M | $0 | — | — |
| Gross profit | — | $795,000 | $0 | — | — |
| Operating income | -$213.1M | -$592.6M | -$99.8M | -$119.7M | -$93.3M |
| Operating expenses | $276.0M | $600.5M | $99.8M | $119.7M | $93.3M |
| Cost of revenue | — | $7.1M | $0 | — | — |
| Cash from operations | -$173.4M | -$130.4M | -$68.0M | -$96.1M | -$68.2M |
| Total assets | $594.8M | $540.6M | $621.5M | $672.1M | $776.2M |
| Total liabilities | $289.1M | $76.8M | $16.4M | $17.1M | $30.2M |
Shares outstanding 348.2M · Free float 40.9%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.